Home/Pipeline/CPT-021

CPT-021

Alzheimer's Disease

Pre-clinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Pre-clinical

Status

Active

Company

Enabled Therapeutics

About Enabled Therapeutics

Enabled Therapeutics is a private, preclinical-stage biotech leveraging its proprietary Capton® platform to create precision neurology therapeutics. Its core innovation involves engineering prodrugs that are activated specifically in diseased brain tissue by the unique biochemical environment of neuropathology, aiming to minimize off-target effects and improve efficacy. The company has gained FDA alignment for its lead candidate, CPT-021, in Alzheimer's disease and is building its leadership team to advance its pipeline. Enabled Therapeutics represents a novel approach to CNS drug delivery, targeting a significant unmet medical need in neurodegeneration.

View full company profile

Therapeutic Areas

Neurodegeneration Central Nervous System

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active